<DOC>
	<DOCNO>NCT00041314</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness carboplatin , gemcitabine , exisulind treat patient advance non-small cell lung cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine 18-month survival rate patient advance non-small cell lung cancer treat carboplatin , gemcitabine , exisulind . - Determine feasibility toxicity regimen patient . - Determine response rate , progression-free survival , overall median survival patient treat regimen . OUTLINE : Patients receive gemcitabine IV 30 minute day 1 8 carboplatin IV 30 minute day 1 . Chemotherapy repeat every 21 day 6 course . Patients also receive oral exisulind twice daily begin day 1 course 1 continue disease progression unacceptable toxicity occurs . Patients follow every 3 month 2 year every 6 month 2 year . PROJECTED ACCRUAL : A total 55 patient accrue study within 6 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Sulindac sulfone</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm nonsmall cell lung cancer ( NSCLC ) Unresectable stage IIIB ( e.g. , pleural effusion ) suitable combine modality therapy OR Stage IV Prior brain metastasis allow provided follow true : Patient complete radiotherapy and/or surgery least 3 week prior study Objective evidence resolution significant improvement brain lesion exist followup CT scan MRI Patient neurologically improve stable PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : Absolute granulocyte count least 1,500/mm^3 WBC least 3,000/mm^3 Hemoglobin least 9 g/L Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.25 mg/dL SGOT great 1.5 time upper limit normal Renal : Creatinine great 2.0 mg/dL OR Creatinine clearance least 50 mL/min Cardiovascular : No prior uncontrolled cardiovascular disease No hospitalization acute myocardial infarction , arrhythmia , congestive heart failure within past 3 month Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective nonhormonal contraception No serious active infection No dementia active psychoses No prior malignancy except nonmetastatic nonmelanoma skin cancer , carcinoma situ cervix , cancer curatively treat surgery smallfield radiotherapy within past 5 year PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 3 week since prior radiotherapy Surgery : See Disease Characteristics Other : At least 1 month since prior investigational agent More 7 day since prior aspirin , sulindac , cyclooxygenase2 ( COX2 ) inhibitor , nonsteroidal antiinflammatory drug ( except ibuprofen naproxen ) No concurrent sulindac COX2 inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2002</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>